Vamikibart

Vamikibart (RG6179) is a monoclonal antibody targeting IL-6 that can be used to inhibit uveal macular edema (UME) and reduce retinal leakage. Vamikibart can reduce anterior chamber (AC) cell density, indicating a reduction in intraocular inflammation. Vamikibart can also be used to assess the leakage dynamics of ultra-wide-angle fluorescein angiography (UWFA) in the UME model to quantify changes in retinal leakage reflecting the effect of UME inhibition[1][2].

Product Specifications

CAS Number

[2744320-12-3]

Product Name Alternative

EBI-031

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vamikibart.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Vamikibart]

Molecular Weight

(145.96 kDa)

References & Citations

[1]Sharma, et al. Longitudinal Quantitative Anterior Chamber Cell Analysis Following Vamikibart Intravitreal Therapy in Patients with Uveitic Macular Edema from the DOVETAIL Clinical Trial. Investigative Ophthalmology & Visual Science 65.7 (2024) : 3028-3028.|[2]Cakir, et al. Longitudinal quantitative ultra-widefield fluorescein angiography leakage dynamics in patients with uveitic macular edema following intravitreal anti-IL-6 therapy with vamikibart. Investigative Ophthalmology & Visual Science 65.7 (2024) : 2628-2628.